In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance ...

Humacyte (HUMA) announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel, ...

The two studies of the company’s engineered vascular tissue saw success with casualties in Ukraine and the US.

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

Backing up a bit, Humacyte filed a BLA in December 2023 after its ATEV demonstrated superiority over a synthetic graft benchmark in a single-arm, open-label, unblinded Phase 2/3 trial (V005).

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte ...

A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in ...

In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks ...

In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – ...

The publication “Bioengineered Human Arteries for the Repair of Vascular Injuries” describes two clinical studies in which the ATEV demonstrated benefits in terms of patency (blood flow), limb ...